Should I buy or sell Praxis Precision Medicines stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRAX shares. View PRAX analyst ratings or view top-rated stocks .

What is Praxis Precision Medicines' stock price target for 2024?

4 Wall Street analysts have issued 12-month target prices for Praxis Precision Medicines' shares. Their PRAX share price targets range from $29.00 to $150.00. On average, they predict the company's share price to reach $103.00 in the next year. This suggests a possible upside of 121.1% from the stock's current price. View analysts price targets for PRAX or view top-rated stocks among Wall Street analysts .

How have PRAX shares performed in 2024?

Praxis Precision Medicines' stock was trading at $22.28 on January 1st, 2024. Since then, PRAX shares have increased by 109.1% and is now trading at $46.59. View the best growth stocks for 2024 here .

When is Praxis Precision Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PRAX earnings forecast .

How were Praxis Precision Medicines' earnings last quarter?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released its earnings results on Tuesday, March, 5th. The company reported ($2.97) earnings per share for the quarter, beating the consensus estimate of ($3.05) by $0.08. The business had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.30 million. Praxis Precision Medicines had a negative trailing twelve-month return on equity of 151.02% and a negative net margin of 5,037.88%.

What ETF holds Praxis Precision Medicines' stock?

Invesco Dorsey Wright Healthcare Momentum ETF holds 25,514 shares of PRAX stock, representing 0.92% of its portfolio.

When did Praxis Precision Medicines' stock split?

Praxis Precision Medicines shares reverse split on the morning of Wednesday, November 29th 2023. The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Praxis Precision Medicines IPO?

Praxis Precision Medicines (PRAX) raised $126 million in an IPO on Friday, October 16th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager.

How do I buy shares of Praxis Precision Medicines?

Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PRAX

Praxis Precision Medicines (PRAX) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free PRAX Stock Alerts

$46.59

-4.19 (-8.25%)

(As of 04/18/2024 ET)

Compare

Today's Range: $45.84
▼
$50.42
50-Day Range: $40.20
▼
$62.18
52-Week Range: $12.45
▼
$67.21

Volume: 204,241 shs
Average Volume: 316,905 shs
Market Capitalization: $616.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $103.00

Get Praxis Precision Medicines alerts:

Praxis Precision Medicines MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 121.1% Upside
$103.00 Price Target
Short Interest: Healthy
2.66% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.56
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($8.64) to ($9.42) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.71 out of 5 stars

Medical Sector

624th out of 918 stocks

Pharmaceutical Preparations Industry

265th out of 402 stocks

3.4

Analyst's Opinion

Consensus Rating
Praxis Precision Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Praxis Precision Medicines has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.66% of the float of Praxis Precision Medicines has been sold short.
Short Interest Ratio / Days to Cover
Praxis Precision Medicines has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Praxis Precision Medicines has recently increased by 5.37%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Praxis Precision Medicines does not currently pay a dividend.
Dividend Growth
Praxis Precision Medicines does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRAX.

2.5

News and Social Media Coverage

News Sentiment
Praxis Precision Medicines has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Praxis Precision Medicines this week, compared to 2 articles on an average week.
Search Interest
Only 11 people have searched for PRAX on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.
MarketBeat Follows
6 people have added Praxis Precision Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Praxis Precision Medicines insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.70% of the stock of Praxis Precision Medicines is held by insiders.
Percentage Held by Institutions
67.84% of the stock of Praxis Precision Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Praxis Precision Medicines are expected to decrease in the coming year, from ($8.64) to ($9.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Praxis Precision Medicines is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Praxis Precision Medicines is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Praxis Precision Medicines has a P/B Ratio of 5.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Praxis Precision Medicines Stock (NASDAQ:PRAX)

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

PRAX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PRAX Stock News Headlines

April 17, 2024 | msn.com

Why an ALS Drug Was Pulled From the Market

April 13, 2024 | americanbankingnews.com

Q2 2024 EPS Estimates for Praxis Precision Medicines, Inc. Lifted by Analyst (NASDAQ:PRAX)

April 19, 2024 | InvestorPlace (Ad)

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 12, 2024 | globenewswire.com

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

April 5, 2024 | globenewswire.com

Praxis Precision Medicines to Participate in Upcoming April Conferences

April 2, 2024 | globenewswire.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 28, 2024 | markets.businessinsider.com

Praxis Precision Medicines Announces Pricing Of Underwritten Public Offering

March 28, 2024 | globenewswire.com

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

April 19, 2024 | InvestorPlace (Ad)

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 27, 2024 | globenewswire.com

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

March 26, 2024 | msn.com

Praxis gains after mid-stage data for epilepsy candidate

March 26, 2024 | markets.businessinsider.com

Praxis Precision Medicines Reports Positive Results From PRAX-628 Study - Quick Facts

March 26, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Praxis Precision Medicines’ PRAX-628 Based on Strong Clinical Trial Outcomes and Market Potential

March 26, 2024 | msn.com

Why Praxis Precision Medicines Stock Is Trading Higher Tuesday

March 26, 2024 | finance.yahoo.com

Top 1% Biotech, Praxis, Releases 'Fireworks' And Catapults To Year-High

March 26, 2024 | seekingalpha.com

Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing

March 26, 2024 | globenewswire.com

Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients

March 25, 2024 | globenewswire.com

Praxis Precision Medicines to Host PRAX-628 Program Update

March 25, 2024 | finance.yahoo.com

A Look At The Intrinsic Value Of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

March 20, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Clene (CLNN) and Jazz Pharmaceuticals (JAZZ)

March 19, 2024 | ca.finance.yahoo.com

PRAX Apr 2024 60.000 call

March 16, 2024 | finance.yahoo.com

PRAX May 2024 22.500 call

March 15, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Allakos (ALLK), Century Therapeutics (IPSC)

March 11, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Praxis Precision Medicines Amidst Promising Pipeline and Financial Stability

March 7, 2024 | finance.yahoo.com

Praxis Precision Medicines Inc (PRAX) Reports Full-Year 2023 Financial Results and Corporate Updates

March 7, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), InMode (INMD) and Teladoc (TDOC)

March 6, 2024 | msn.com

Praxis Precision Medicines files for $750M mixed shelf offering

See More Headlines

Receive PRAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PRAX
CUSIP: N/A
CIK: 1689548
Web: www.praxismedicines.com
Phone: 617-300-8460
Fax: N/A
Employees: 82
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $103.00
High Stock Price Target: $150.00
Low Stock Price Target: $29.00
Potential Upside/Downside: +121.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($23.66)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-123,280,000.00
Net Margins: -5,037.88%
Pretax Margin: -5,037.88%
Return on Equity: -151.02%
Return on Assets: -115.60%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.39
Quick Ratio: 5.39

Sales & Book Value

Annual Sales: $2.45 million
Price / Sales: 251.78
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.92 per share
Price / Book: 5.88

Miscellaneous

Outstanding Shares: 13,240,000
Free Float: 12,881,000
Market Cap: $616.85 million
Optionable: Optionable
Beta: 2.89

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Marcio Silva De'Souza M.B.A. (Age 44)
President, CEO & Director
Comp: $1.18M
Mr. Timothy Edwin Kelly (Age 50)
CFO & Treasurer
Comp: $691.58k
Mr. Alex Nemiroff J.D. (Age 44)
General Counsel & Secretary
Comp: $577.34k
Dr. Steven Petrou B.Sc. (Hons.)
Ph.D., Co-Founder & Chief Scientific Officer
Lauren Mastrocola
VP of Finance & Principal Accounting Officer
Dr. Karl Hansen Ph.D.
Chief Technical Operations Officer
Alex Kane
VP of Investor Relations & Corporate Communications
Ms. Kelly McCue
Chief People Officer
Ms. Alyssa J. S. Wyant (Age 49)
Chief Regulatory & Quality Officer
Ms. Megan T. Sniecinski (Age 42)
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRAX Stock Analysis - Frequently Asked Questions

Should I buy or sell Praxis Precision Medicines stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRAX shares.
View PRAX analyst ratings or view top-rated stocks.
What is Praxis Precision Medicines' stock price target for 2024?: 4 Wall Street analysts have issued 12-month target prices for Praxis Precision Medicines' shares. Their PRAX share price targets range from $29.00 to $150.00. On average, they predict the company's share price to reach $103.00 in the next year. This suggests a possible upside of 121.1% from the stock's current price.
View analysts price targets for PRAX or view top-rated stocks among Wall Street analysts.
How have PRAX shares performed in 2024?: Praxis Precision Medicines' stock was trading at $22.28 on January 1st, 2024. Since then, PRAX shares have increased by 109.1% and is now trading at $46.59.
View the best growth stocks for 2024 here.
When is Praxis Precision Medicines' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PRAX earnings forecast.
How were Praxis Precision Medicines' earnings last quarter?: Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released its earnings results on Tuesday, March, 5th. The company reported ($2.97) earnings per share for the quarter, beating the consensus estimate of ($3.05) by $0.08. The business had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.30 million. Praxis Precision Medicines had a negative trailing twelve-month return on equity of 151.02% and a negative net margin of 5,037.88%.

What ETF holds Praxis Precision Medicines' stock?: Invesco Dorsey Wright Healthcare Momentum ETF holds 25,514 shares of PRAX stock, representing 0.92% of its portfolio.
When did Praxis Precision Medicines' stock split?: Praxis Precision Medicines shares reverse split on the morning of Wednesday, November 29th 2023. The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
When did Praxis Precision Medicines IPO?: Praxis Precision Medicines (PRAX) raised $126 million in an IPO on Friday, October 16th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager.
How do I buy shares of Praxis Precision Medicines?: Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRAX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial